Mouse Ly9/SLAMF3/CD229 ELISA Kit PicoKine®, Carrier-free

T-lymphocyte surface antigen Ly-9 is a protein that in humans is encoded by the LY9 gene. This gene is mapped to 1 H3; 1 79.54 cM. Mature human CD229 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig?like V-set and two Ig?like truncated C2-set domains. It also shows a 22 aa transmembrane segment, and a 179 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs ITSMs. The ECD of human CD229 shares 57%?59% aa sequence identity with mouse and rat CD229. Within the first two Ig?like domains that are common to all SLAM proteins, human CD229 shares 24%?39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. Alternate splicing generates two additional isoforms that lack the juxtamembrane Ig?like domain or short cytoplasmic region. CD229 is expressed on T and B cells, thymocytes, and more weakly on NK cells. Homophilic binding between CD229 molecules is mediated by the N-terminal Ig?like domain. Human and mouse CD229 exhibit cross-species binding. Antigen stimulation of lymphocytes induces CD229 clustering to sites of T cell - B cell contact. Two tyrosines in the cytoplasmic domain are required for association of CD229 with the adaptor proteins AP-2 (μ2 chain) and GRB-2 and both are required for CD229 internalization.

<table cellpadding="3"><tr><th>Lots</th><th>Lot 1 (pg/ml)</th><th>Lot 2 (pg/ml)</th><th>Lot 3 (pg/ml)</th><th>Lot 4 (pg/ml)</th><th>Mean (pg/ml)</th><th>Standard Deviation</th><th>CV (%)</th></tr><tr><td>Sample 1</td><td>98</td><td>102</td><td>93</td><td>100</td><td>98</td><td>3.34</td><td>3.4%</td></tr><tr><td>Sample 2</td><td>625</td><td>655</td><td>616</td><td>684</td><td>645</td><td>26.74</td><td>4.1%</td></tr><tr><td>Sample 3</td><td>2210</td><td>2338</td><td>2344</td><td>1958</td><td>2212</td><td>156.38</td><td>7.0%</td></tr></table>*number of samples for each test n=16.

T-lymphocyte surface antigen Ly-9; Cell surface molecule Ly-9; Lymphocyte antigen 9; SLAM family member 3; SLAMF3; Signaling lymphocytic activation molecule 3; CD229; Ly9; Ly-9

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A. Promotes recruitment of RORC to the IL-17 promoter. May be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. May disable autoantibody responses and inhibit IFN-gamma secretion by CD4+ T-cells. May negatively regulate the size of thymic innate CD8+ T-cells and the development of invariant natural killer T (iNKT) cells. Can promote natural killer (NK) cell activation.

Description|Quantity Pre-coated 96-well strip microplate|1 Standard|2 vials Biotinylated antibody (100x)|100ul Avidin-Biotin-Peroxidase Complex (100x)|100ul Sample Diluent|30ml Antibody Diluent|12ml Avidin-Biotin-Peroxidase Diluent|12ml Color Developing Reagent (TMB)|10ml Stop Solution|10ml Wash Buffer (25x)|20ml Adhesive plate sealers|4

Store at 4℃ for 6 months, at -20℃ for 12 months. Avoid multiple freeze-thaw cycles (Ships with gel ice, can store for up to 3 days in room temperature. Freeze upon receiving.)